PIRAMAL PHARMA
Quarterly Results Analysis [Sep2024]
PIRAMAL PHARMA Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,242 Cr | ₹1,951 Cr | ₹2,552 Cr | ₹1,959 Cr | ₹1,911 Cr | ₹1,749 Cr | ₹2,164 Cr | ₹1,716 Cr |
Expenses | ₹1,900 Cr | ₹1,747 Cr | ₹2,022 Cr | ₹1,690 Cr | ₹1,646 Cr | ₹1,617 Cr | ₹1,812 Cr | ₹1,629 Cr |
Operating Income | ₹342 Cr | ₹204 Cr | ₹530 Cr | ₹268 Cr | ₹266 Cr | ₹132 Cr | ₹351 Cr | ₹87 Cr |
Other Income | ₹61 Cr | ₹20 Cr | ₹26 Cr | ₹62 Cr | ₹49 Cr | ₹38 Cr | ₹25 Cr | ₹83 Cr |
Interest | ₹108 Cr | ₹107 Cr | ₹114 Cr | ₹106 Cr | ₹110 Cr | ₹119 Cr | ₹104 Cr | ₹95 Cr |
Depreciation | ₹192 Cr | ₹185 Cr | ₹196 Cr | ₹186 Cr | ₹185 Cr | ₹174 Cr | ₹184 Cr | ₹164 Cr |
Profit Before Tax | ₹103 Cr | ₹-67 Cr | ₹215 Cr | ₹5 Cr | ₹20 Cr | ₹-122 Cr | ₹87 Cr | ₹-89 Cr |
Profit After Tax | ₹5 Cr | ₹-111 Cr | ₹89 Cr | ₹-4 Cr | ₹-14 Cr | ₹-113 Cr | ₹42 Cr | ₹-106 Cr |
EPS | ₹0.17 | ₹-0.67 | ₹0.77 | ₹0.08 | ₹0.04 | ₹-0.81 | ₹0.41 | ₹-0.74 |
Industry Peers & Returns | 1W | 1M | 1Y |
PIRAMAL PHARMA | -4.3% | -5.8% | 62.2% |
SUN PHARMACEUTICAL INDUSTRIES | -3.7% | -2.5% | 31.9% |
CIPLA | -3.2% | 0% | 8.2% |
DR REDDYS LABORATORIES | -2.4% | 7.3% | 15.3% |
ZYDUS LIFESCIENCES | 2% | 2.3% | 37.9% |
DIVIS LABORATORIES | 2.3% | 2.1% | 46.9% |
MANKIND PHARMA | -7.1% | 1.2% | 20.5% |
TORRENT PHARMACEUTICALS | -2.1% | -2.8% | 37.8% |
LUPIN | -4.3% | 3.8% | 53.3% |
PIRAMAL PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 14.89 % |
Y-o-Y | 17.28 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹2,242 Cr | 14.89 | |
Jun2024 | ₹1,951 Cr | -23.56 | |
Mar2024 | ₹2,552 Cr | 30.32 | |
Dec2023 | ₹1,959 Cr | 2.47 | |
Sep2023 | ₹1,911 Cr | 9.29 | |
Jun2023 | ₹1,749 Cr | -19.17 | |
Mar2023 | ₹2,164 Cr | 26.08 | |
Dec2022 | ₹1,716 Cr | - |
PIRAMAL PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 67.05 % |
Y-o-Y | 28.60 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹342 Cr | 67.05 | |
Jun2024 | ₹204 Cr | -61.41 | |
Mar2024 | ₹530 Cr | 97.46 | |
Dec2023 | ₹268 Cr | 1.03 | |
Sep2023 | ₹266 Cr | 100.76 | |
Jun2023 | ₹132 Cr | -62.33 | |
Mar2023 | ₹351 Cr | 302.23 | |
Dec2022 | ₹87 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 45.42 % |
Y-o-Y | 9.64 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 15.24% | 45.42 | |
Jun2024 | 10.48% | -49.52 | |
Mar2024 | 20.76% | 51.53 | |
Dec2023 | 13.7% | -1.44 | |
Sep2023 | 13.9% | 83.62 | |
Jun2023 | 7.57% | -53.39 | |
Mar2023 | 16.24% | 219.06 | |
Dec2022 | 5.09% | - |
PIRAMAL PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | Positive |
Y-o-Y | Positive |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹5 Cr | Positive | |
Jun2024 | ₹-111 Cr | Negative | |
Mar2024 | ₹89 Cr | Positive | |
Dec2023 | ₹-4 Cr | Negative | |
Sep2023 | ₹-14 Cr | Negative | |
Jun2023 | ₹-113 Cr | Negative | |
Mar2023 | ₹42 Cr | Positive | |
Dec2022 | ₹-106 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | Positive |
Y-o-Y | Positive |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 0.24 % | Positive | |
Jun2024 | -5.69 % | Negative | |
Mar2024 | 3.5 % | Positive | |
Dec2023 | -0.2 % | Negative | |
Sep2023 | -0.74 % | Negative | |
Jun2023 | -6.46 % | Negative | |
Mar2023 | 1.96 % | Positive | |
Dec2022 | -6.16 % | - |
PIRAMAL PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | Positive |
Y-o-Y | 325.00 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹0.17 | Positive | |
Jun2024 | ₹-0.67 | Negative | |
Mar2024 | ₹0.77 | 862.50 | |
Dec2023 | ₹0.08 | 100.00 | |
Sep2023 | ₹0.04 | Positive | |
Jun2023 | ₹-0.81 | Negative | |
Mar2023 | ₹0.41 | Positive | |
Dec2022 | ₹-0.74 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD